THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2017

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2017

WEBINARS

Register Now and
On Demand

Home » Archive by Tags

Articles tagged with: Qiagen

Qiagen, Centogene join forces on rare disease testing, 1/18

January 2018—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight research and clinical testing solutions in rare genetic diseases. The collaboration includes the integration of Centogene’s CentoMD rare disease variant database into Qiagen’s bioinformatics offering to enhance test interpretation.

Qiagen, Centogene join forces on rare disease testing

Oct. 17, 2017—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight …

Qiagen joins Cancer-ID consortium, 8/17

August 2017—Qiagen has joined Cancer-ID, a public-private consortium of 36 partners from 13 countries that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

Qiagen launches JAK2 test

April 17, 2017—Qiagen launched its Ipsogen JAK2 RGQ PCR Kit, which was cleared by the Food and Drug Administration as …

Singulex, Qiagen to develop companion diagnostics, 4/17

April 2017—Singulex has entered into a strategic collaboration with Qiagen to develop companion diagnostics. Through the collaboration, Qiagen will have access to Singulex’s Single Molecule Counting (SMC) immunodiagnostic platform, adding immunoassay capabilities to Qiagen’s existing molecular testing services for the development of companion diagnostics.

TB test submitted for PMA, 3/17

March 2017—Qiagen announced it submitted its QuantiFeron-TB Gold Plus, the fourth generation of the modern blood test for detecting tuberculosis infection, for premarket approval by the Food and Drug Administration.

CALR mutation assay for MPN diagnosis, 2/17

February 2017—Qiagen announced the European launch of its CE-IVD marked calreticulin mutation assay to aid in establishing the diagnosis of myeloproliferative neoplasms. The ipsogen CALR RGQ PCR kit is intended for the detection of CALR mutations in genomic DNA from subjects suspected of myeloproliferative neoplasms. It enables identification of the two major CALR mutations, type 1 and type 2, and detects additional mutations in the CALR exon 9 region.

All-in-one library prep kit, 2/17

February 2017—Qiagen launched the QIAseq cfDNA All-in-One kit, combining cell-free DNA extraction and library preparation in a dedicated solution for liquid biopsy analysis on next-generation sequencing platforms. The kit integrates with Qiagen’s PAXgene Blood ccfDNA tube as well as with the company’s bioinformatics workflow for cfDNA, creating a streamlined testing solution that aims to allow faster, more convenient, and reliable analysis of cell-free DNA from sample collection to interpreted result.

Qiagen enhances GeneReader NGS system

Jan. 20, 2017—Qiagen announced a comprehensive range of enhancements for the GeneReader NGS system, in particular the launch of gene …

Single-cell analysis instrument, 1/17

January 2017—Qiagen launched its QIAscout, a novel instrument for isolation of viable single cells from samples to enable single-cell analysis for next-generation sequencing, polymerase chain reaction, and other downstream applications.

X